Table 3.

Annual rates of noninvasive breast cancer and uterine disease/hysterectomy—NSABP STAR Trial (P-2)

Disease/uterine event typeEvents, nRate per 1,000RR*RR (95% CI)
TamoxifenRaloxifeneTamoxifenRaloxifeneDifference
Noninvasive breast cancer
    DCIS70861.151.40−0.251.220.88–1.69
    LCIS33340.540.55−0.011.020.61–1.70
    Mixed8170.130.28−0.152.110.86–5.64
    Total1111371.832.23−0.401.220.95–1.59
Uterine disease and hysterectomy
Invasive Cancer65372.251.231.020.550.36–0.83
Hyperplasia§126254.400.843.560.190.12–0.29
    Without atypia§104213.630.702.930.190.11–0.31
    With atypia§2240.770.130.640.170.04–0.51
Hysterectomy during follow-up34916212.085.416.670.450.37–0.54

Abbreviations: CI, confidence interval; DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ; NSABP STAR, National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene; RR, risk ratio.

  • *Risk ratio for women in the raloxifene group compared with women in the tamoxifen group.

  • Rate in the tamoxifen group minus rate in the raloxifene group.

  • Women at risk were those with an intact uterus at entry (see Table 1).

  • §Among women not diagnosed with uterine cancer.